TXMDEarnings•businesswire•
TherapeuticsMD Announces Second Quarter 2025 Financial Results
Sentiment:Negative (30)
Summary
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $545 thousand, or $0.05 per basic and diluted common share, compared to a net loss of $(1.05) million, or $(0.09) per basic and diluted
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by businesswire